Lipidomics in Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Lipidomics in Breast Cancer

Fig. 11.1 Lipid structure representations. Examples of structures from the major classes of biological lipids (cholesterol, free fatty acid, triglyceride, phospholipid) are shown Living cells acquire fatty acids for their…

read more

Systems Biology and Integrative Omics in Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Systems Biology and Integrative Omics in Breast Cancer

Fig. 17.1 Some characteristic issues of complex biological systems. We can notice that these are interdependent phenomena that cannot be treated separately, hence the need for integrative methodologies HTOTs provide…

read more

Clinical Trial Endpoints in Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Clinical Trial Endpoints in Breast Cancer

Fig. 27.1 Comparison of overall survival and surrogate endpoints Disease-Free Survival (DFS) Disease-free survival (DFS) is defined as the time from randomization until recurrence of tumor or death from any…

read more

Breast Cancer Stem Cells and Cellomics

Feb 12, 2017 by in ONCOLOGY Comments Off on Breast Cancer Stem Cells and Cellomics

Gene Description Function(s) Signature type and importance Annexin A5 (ANXA5) Gene encodes indirect inhibitor of the thromboplastin-specific complex involved in the blood coagulation cascade Calcium ion binding, calcium-dependent phospholipid binding,…

read more

Breast Cancer Therapy–Classical Therapy, Drug Targets, and Targeted Therapy

Feb 12, 2017 by in ONCOLOGY Comments Off on Breast Cancer Therapy–Classical Therapy, Drug Targets, and Targeted Therapy

Drug class Agents Alkylating agents Cyclophosphamide Antimetabolites 5-Fluouracil (5-FU), methotrexate, capecitabine, gemcitabine Platinum salts Cisplatin, carboplatin, oxaliplatin Anthracyclines Daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone Topoisomerase I inhibitors Irinotecan Topoisomerase II inhibitors…

read more
Get Clinical Tree app for offline access